All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-06-06.
From the record
Retractable Technologies, Inc's filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2025-06-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+2.8% a year over 10 filed years; profitable in 4 of 10.
From the record
Retractable Technologies, Inc's 10 filed years say what it did: revenue went from $30 million in fiscal 2016 to $38 million in fiscal 2025, up 2.8% a year; it rose in 5 of 9 years; the deepest fall was 82% from fiscal 2021 to fiscal 2024; net income was positive in 4 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 9.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Retractable Technologies, Inc's shareholder treatment is put at 9.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 5% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -17%: lost 17¢ per shareholder dollar. Leverage 48%: owes 48¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Retractable Technologies, Inc lost about 17 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 48 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 28% of 109 in its family; net margin -32.8%.
From the record
Retractable Technologies, Inc's standing among 109 graded names in its industry family: revenue of $38 million in fiscal 2025 ranks in the bottom 35% by size; a net margin of -32.8% ranks in the bottom 41%; revenue growth of -26.1% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 9.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Retractable Technologies, Inc's leadership is put at 9.7 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the top 3% of 108 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 22% of 104 in its family for room to expand.
From the record
Retractable Technologies, Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against debt of $896 thousand leaves 1.2% of its assets as net cash, bottom 35% of its family; cash from operations less capital spending is -18.5% of revenue (bottom 42%); a gross margin of 0.1% (bottom 4%); research spending of 1.8% of revenue (bottom 7%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 32% of 105 in its family for growth drivers.
From the record
Retractable Technologies, Inc's growth drivers, from the filed years to fiscal 2025: revenue grew -26.1% a year over the last three filed years against 2.8% over all 10, slowing (bottom 7% of its family); the newest year grew 15.8% (top 43%); research spending grew 8.7% a year (top 40%); capital spending grew -70.9% a year (bottom 4%) (its annual reports). Retractable Technologies, Inc reported 4 product lines in fiscal 2025: Syringes at $25 million (65%), Easy Point Needles at $12 million (31%), Blood Collection Products at $1 million (4%), and 1 more; 2 of 4 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 39% of 88 in its family for expectations against reality.
From the record
Retractable Technologies, Inc's newest year against its own record: revenue of $38 million in fiscal 2025 came in 96% above the $20 million its prior three years' pace pointed to (top 2% of its family); net income of $13 million against a prior three-year average of $5 million (bottom 9%); a net margin of -32.8% against -15.6% before (bottom 10%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made